Evidence map›Paper›PMID 31439591›Full record

ArticleAnnals of the rheumatic diseases2019

Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis.

Minghua Wu, Brian Skaug, Xiongjie Bi, Tingting Mills, Gloria Salazar, Xiaodong Zhou, John Reveille, Sandeep K Agarwal, Michael R Blackburn, Maureen D Mayes and 1 more

Open access · greenAbstract read
In one paragraph

Article in Annals of the rheumatic diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 103 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. The Maternal Blood Transcriptome Reflects Changes in Fetal Growth and Is an Accurate Predictor of Birth Weight in Cattle.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Minghua WuDivision of Rheumatology and Clinical Immunogenetics, Department of Internal Medicine, University of Texas McGovern Medical School at Houston, Houston, Texas, USA minghua.wu@uth.tmc.edu.ORCID 0000-0002-0388-2032
Brian SkaugDivision of Rheumatology and Clinical Immunogenetics, Department of Internal Medicine, University of Texas McGovern Medical School at Houston, Houston, Texas, USA.ORCID 0000-0002-6689-4655
Xiongjie BiFirst Affiliated Hospital of Guangxi University of Science And Technology, Liuzhou, Guangxi, China.
Tingting MillsDepartment of Biochemistry and Molecular Biology, University of Texas McGovern Medical School at Houston, Houston, Texas, USA.
Gloria SalazarDivision of Rheumatology and Clinical Immunogenetics, Department of Internal Medicine, University of Texas McGovern Medical School at Houston, Houston, Texas, USA.
Xiaodong ZhouDivision of Rheumatology and Clinical Immunogenetics, Department of Internal Medicine, University of Texas McGovern Medical School at Houston, Houston, Texas, USA.
John ReveilleDivision of Rheumatology and Clinical Immunogenetics, Department of Internal Medicine, University of Texas McGovern Medical School at Houston, Houston, Texas, USA.
Sandeep K AgarwalDepartment of Medicine, Section of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, Texas, USA.
Michael R BlackburnDepartment of Biochemistry and Molecular Biology, University of Texas McGovern Medical School at Houston, Houston, Texas, USA.
Maureen D MayesDivision of Rheumatology and Clinical Immunogenetics, Department of Internal Medicine, University of Texas McGovern Medical School at Houston, Houston, Texas, USA.
Shervin AssassiDivision of Rheumatology and Clinical Immunogenetics, Department of Internal Medicine, University of Texas McGovern Medical School at Houston, Houston, Texas, USA.ORCID 0000-0002-8059-9978
The University of Texas Health Science Center at Houston · USBaylor College of Medicine · USGuangxi University · CNTexas Medical Center · US

Funding

CFlm25 mediated alternative polyadenylation regulates fibrosis in systemic sclerosisR01AR073284 · NIAMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ASSASSI, SHERVIN, MILLS, TINGTING WENG · 2019 to 2023
$1.7M
NIAMS NIH HHS R01 AR073284
6 · The paper itself

Abstract

objectivesThere is considerable evidence that implicates dysregulation of type I interferon signalling (or type I IFN signature) in the pathogenesis of systemic sclerosis (SSc). Interferon regulatory factor 7 (IRF7) has been recognised as a master regulator of type I IFN signalling. The objective of this study was to elucidate the role of IRF7 in dermal fibrosis and SSc pathogenesis.

methodsSSc and healthy control skin biopsies were investigated to determine IRF7 expression and activation. The role of IRF7 in fibrosis was investigated using IRF7 knockout (KO) mice in the bleomycin-induced and TSK/+mouse models. In vitro experiments with dermal fibroblasts from patients with SSc and healthy controls were performed.

resultsIRF7 expression was significantly upregulated and activated in SSc skin tissue and explanted SSc dermal fibroblasts compared with unaffected, matched controls. Moreover, IRF7 expression was stimulated by IFN-α in dermal fibroblasts. Importantly, IRF7 co-immunoprecipitated with Smad3, a key mediator of transforming growth factor (TGF)-β signalling, and IRF7 knockdown reduced profibrotic factors in SSc fibroblasts. IRF7 KO mice demonstrated attenuated dermal fibrosis and inflammation compared with wild-type mice in response to bleomycin. Specifically, hydroxyproline content, dermal thickness as well as Col1a2, ACTA2 and interleukin-6 mRNA levels were significantly attenuated in IRF7 KO mice skin tissue. Furthermore, IRF7 KO in TSK/+mice attenuated hydroxyproline content, subcutaneous hypodermal thickness, Col1a2 mRNA as well as α-smooth muscle actin and fibronectin expression.

conclusionsIRF7 is upregulated in SSc skin, interacts with Smad3 and potentiates TGF-β-mediated fibrosis, and therefore may represent a promising therapeutic target in SSc.

Indexed as

AnimalsBleomycinDisease Models, AnimalFibroblastsFibrosisHumansInflammationInterferon Regulatory Factor-7MiceMice, KnockoutScleroderma, SystemicSignal TransductionSkinSmad3 ProteinTransforming Growth Factor betaUp-RegulationBleomycinInterferon Regulatory Factor-7Smad3 ProteinTransforming Growth Factor betaautoimmune diseasesfibroblastssystemic sclerosis

Identifiers

PMID31439591
PMCPMC7167109
OpenAlexW2969918848

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.